Question

The first approved treatment for primary progressive multiple sclerosis, ocrelizumab, targets this antigen. For 10 points each:
[10m] Name this antigen found on the surface of B cells. This antigen is targeted by the first antibody approved for cancer patients, rituximab.
ANSWER: CD20 [accept MS4A1]
[10h] In addition to attracting NK cells in antibody-dependent cellular cytotoxicity, rituximab also induces complement-dependent cytotoxicity. This protein complex binds to antibody-antigen complexes in the classical complement pathway.
ANSWER: C1 [or complement component 1; accept C1q or complement component 1q]
[10e] The suffix “-mab” in rituximab and ocrelizumab refers to them being medicines composed of these antibodies. Fused hybridomas produce these antibodies which target a single epitope.
ANSWER: monoclonal antibodies [or mAb]
<Science - Biology>

Back to bonuses

Summary

2024 ARGOS @ Chicago11/23/2024Y613.33100%33%0%
2024 ARGOS @ Columbia11/23/2024Y33.3333%0%0%
2024 ARGOS @ McMaster11/17/2024Y58.0060%20%0%

Data

Ryan Wesley Routh's 10 000 NATO-trained Afghan QuizbowlersYou cannot go to Aarhus to see his peat-brown head / With eyes like ripening fruit0000
I'd prefer to have the team name be Christensen et al. than anything that Erik cooks up She Dicer On My Argonaute Till I RNA Interfere0000
Simpson Agonistes: The Crisis of DonutModerator Can't Neg me While in Alpha001010
The Only Existing Manuscript from A Clockwork OrangeTensei Shitara Flashcard Data Ken001010
Communism is Soviet power plus the yassification of the whole countryas rational as the square root of two power bottoms1001020